CA2861556C — Lactam derivatives useful as inhibitors of mutant idh1
Assigned to Les Laboratoires Servier SAS · Expires 2021-07-13 · 5y expired
What this patent protects
Provided herein are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2. The methods include use of a compound of formula I, or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof: wherein RI, R2, R3, R4 and ring A are…
USPTO Abstract
Provided herein are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2. The methods include use of a compound of formula I, or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof: wherein RI, R2, R3, R4 and ring A are defined herein.
Drugs covered by this patent
- Tibsovo (IVOSIDENIB) · Servier
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.